Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231219 | 1.00 | HSD17B10 (0.55) | HSD17B10HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL889059 | 1.00 | HSD17B10 (0.55) | HSD17B10HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL525478 | 0.95 | HPGD (0.50) | HSD17B10HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL10082580 | 0.95 | HPGD (0.50) | HSD17B10HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL15317053 | 0.95 | HPGD (0.50) | HSD17B10HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5275535 | 0.90 | HSD17B10 (0.47) | HSD17B10HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL4919669 | 0.90 | HSD17B10 (0.47) | HSD17B10HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL29530476 | 0.89 | HSD17B10 (0.46) | HSD17B10HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1198458 | 0.87 | PTPN2 (0.47) | HSD17B10HPGDNPC1LMNANPSR1 | |
| SCHEMBL5171011 | 0.85 | HSD17B10 (0.49) | HSD17B10HPGDSMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | BRIDGE MEDICINES (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4583869-A2 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | Bridge Medicines (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025111492-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | UNIV NORTHWESTERN (US) | 2025-05-29 | — | — | US | disclosed |
| EP-0440670-B1 | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1996-03-06 | — | — | EP | disclosed |
| US-5409946-A | Antiepileptic agent | ABBOTT LABORATORIES (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0588917-A4 | — | — | 1994-04-13 | — | — | EP | disclosed |
| EP-0588917-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-03-30 | — | — | EP | disclosed |
| US-5225567-A | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| WO-1992021339-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
| US-5157124-A | Improving mental performance | THE UPJOHN COMPANY (US) | 1992-10-20 | — | — | US | disclosed |
| US-5137905-A | Cholinergic agonists; analgesics; cognition activators | THE UPJOHN COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0440670-A1 | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. | UPJOHN CO (US) | 1991-08-14 | — | — | EP | disclosed |
| WO-1990004588-A1 | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | HSD17B10 3790/4885HPGD 647/4885SMN1; SMN2 3339/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | HSD17B10 3790/4885HPGD 647/4885SMN1; SMN2 3339/4885 |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | HSD17B10 1278/4885HPGD 13/4885SMN1; SMN2 71/4885 |
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | MLLT3, MLLT1, FLT3 | HSD17B10 2268/4885HPGD 4318/4885SMN1; SMN2 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.